Why should I try your new model? A GSK perspective on adoption of novel preclinical models in drug development
Director, Target & Pathway Validation, GlaxoSmithKline
Dr. Klein received his Ph.D. from Universite Claude Bernard, Lyon, France in the laboratory of Dr Yamaski at the International Agency for Research on Cancer (WHO). For his thesis, Dr Klein developed 3D cell models using primary human cancer cells. During his postdoctoral training at the NIEHS, NIH, Dr Klein became expert in human and rodent primary bone marrow stem cell models. Dr. Klein joined GlaxoSmithKline in 1998 and one of his first projects was to culture all the different human primary cell types available from vendors to obtain gene profiles from various human cell types. Dr. Klein is currently Scientific Director at GSK where he manages a group of cellular and molecular biologists and histologists and leads a program on validation of human disease relevant models. This effort includes internal development and validation of physiologically relevant models as well as interacting with external companies and universities that create novel cellular models. The incorporation of human disease relevant models in the drug development process is critical for pharmaceutical companies for reducing the current drug attrition in clinical phases.